Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Quadruple-blind Health Services Research

A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes.

Height · Cognitive Function · Weight Gain

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Change Mean Percentile Score in Double Trouble — 168.55; 129.46 percent change from baseline — p=0.488445

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
NuBest Tall Growth Protein Powder (Dietary_supplement); Placebo Powder (Dietary_supplement)
Age
Pediatric · 10+ yrs
Sex
All
Sponsor
NuBest
Primary completion
Feb 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Change Mean Percentile Score in Double Trouble
168.55; 129.46 0.488445
PRIMARY
IChange Mean Percentile Score in Feature Match
34.60; 58.20 0.98317
PRIMARY
Change Mean Percentile Score in Grammatical Reasoning
56.59; 88.39 0.98317
PRIMARY
Change Mean Percentile Score in Digit Span
28.02; 19.69 0.919209
PRIMARY
Change Mean Percentile Score in Token Search
6.26; 40.20 0.919209
SECONDARY
Increase in Height
0.89; 1.16; 3.25; 1.67; 3.47; 3.49 0.954882
SECONDARY
Changes in Weight
4.67; 4.50; 5.52; 2.29; 7.53; 4.65 0.483382
SECONDARY
Changes in Overall Health as Reported by Parents
0.45; 0.19; 1.22; 6.73; -0.51; 14.42 0.999216
SECONDARY
Change in Parents' Perception of the Child's Health in the Future.
16.99; 3.53; 19.87; 7.33; 19.55; 9.78 0.999851
SECONDARY
Parents' Perception of the Change in Child's Health Compared to One Month Ago.
12.82; 8.01; 18.27; 17.33; 20.19; 25.00 0.999851
SECONDARY
Change in Child's Energy Levels as Reported by Parents
9.17; 11.47; 5.83; 13.20; 11.86; 26.88 0.999835
SECONDARY
Changes in Limitations When Completing High-Intensity Activity
8.33; 3.85; 12.18; 0.00; 6.41; -13.77 0.999851
SECONDARY
Changes in Limitations When Completing Moderate-Intensity Activity
0.64; 8.33; 0.64; 4.67; -3.21; -9.42 0.999732
SECONDARY
Changes in Limitations When Moving Around
7.69; 14.10; 7.69; 6.67; 3.85; -1.45 0.999851
SECONDARY
Changes in Limitations When Walking 100 Meters or Climbing a Flight of Stairs
-0.96; 6.41; 2.88; -1.33; -2.88; -1.45 0.999387
SECONDARY
Change in Limitations When Bending, Lifting, or Stooping.
5.77; 6.41; 3.85; 0.67; -3.85; -1.45 0.999975
SECONDARY
Change in Limitations in the Kind of Schoolwork or Activities Undertaken.
5.77; -0.96; 5.77; -4.00; 1.92; -5.43 0.981906
SECONDARY
Change in Limitations in the Amount of Time Spent Completing Schoolwork or Activities.
19.23; -5.13; 0.00; -3.00; 7.69; -9.78 0.55783
SECONDARY
Change in Limitations During the Completion of Schoolwork or Activities.
5.77; -0.64; 9.62; -2.00; 3.85; -13.04 0.795476
SECONDARY
Change in Parents' Perception of Child's Health Compared to Other Children.
-1.92; 1.60; 2.56; -4.00; -16.67; 1.45 0.995367
SECONDARY
Change in Parents' Perception of Child's Immunity
-5.77; 18.59; -11.86; 1.33; -8.01; 12.68 0.882016
SECONDARY
Change in Parents' Worry About Child's Health
7.37; -9.29; 12.18; 1.33; 2.24; 1.45 0.999975
SECONDARY
Change in Parent-reported Frequency of Child's Stomach Aches
-4.49; -9.62; -7.69; -11.00; -10.26; -7.97 0.999851
SECONDARY
Change in Parent-reported Frequency of Child's Difficulty Going to the Toilet
-6.79; -7.05; -10.19; -7.00; -18.21; -11.96 >0.999999
SECONDARY
Change Mean Percentile Score in Double Trouble - NuBest Group Only (Within-Group Analysis)
28; 48.67 0.0003 sig
SECONDARY
Change Mean Percentile Score in Feature Match - NuBest Group Only (Within-Group Analysis)
39.58; 45.75 0.2698
SECONDARY
Change Mean Percentile Score in Grammatical Reasoning Match - NuBest Group Only (Within-Group Analysis)
47.42; 56.54 0.2698
SECONDARY
Change Mean Percentile Score in Digit Span - NuBest Group Only (Within-Group Analysis)
42.29; 50.88 0.2137
SECONDARY
Change Mean Percentile Score in Token Search - NuBest Group Only (Within-Group Analysis)
53.17; 53.04 0.8639
SECONDARY
Change Mean Percentile Score in Double Trouble - Placebo Group Only (Within-Group Analysis)
33.73; 49.62 0.239
SECONDARY
Change Mean Percentile Score in Feature Match - Placebo Group Only (Within-Group Analysis)
40.81; 45.29 0.6088
SECONDARY
Change Mean Percentile Score in Grammatical Reasoning - Placebo Group Only (Within-Group Analysis)
47.05; 54.33 0.5738
SECONDARY
Change Mean Percentile Score in Digit Span - Placebo Group Only (Within-Group Analysis)
52.57; 57.62 0.6088
SECONDARY
Change Mean Percentile Score in Token Search - Placebo Group Only (Within-Group Analysis)
48.62; 55.62 0.4942
SECONDARY
Increase in Height - Nubest Group Only (Within-Group Analysis)
61.69; 62.01; 63.33; 63.24 0.7419
SECONDARY
Increase in Height - Placebo Group Only (Within-Group Analysis)
60.66; 62.41; 62.71; 63.05 0.7708
SECONDARY
Changes in Weight - Nubest Group Only (Within-Group Analysis)
121.68; 126.38; 124.36; 123.82 0.0219 sig
SECONDARY
Changes in Weight - Placebo Group Only (Within-Group Analysis)
130.43; 137.92; 133.06; 128.99 0.0695
SECONDARY
Changes in Overall Health as Reported by Parents - NuBest Group Only (Within-Group Analysis)
4.33; 4.29; 4.33; 4.25; 4.42; 4.33 >0.9999
SECONDARY
Change in Parents' Perception of the Child's Health in the Future - NuBest Group Only (Within-Group Analysis)
3.38; 3.63; 3.71; 3.67; 3.58; 3.71 >0.9999
SECONDARY
Parents' Perception of the Change in Child's Health Compared to One Month Ago - NuBest Group Only (Within-Group Analysis)
3.17; 3.58; 3.63; 3.71; 3.75; 3.54 0.4598
SECONDARY
Change in Child's Energy Levels as Reported by Parents - NuBest Group Only (Within-Group Analysis)
3.88; 4.21; 4.04; 4.29; 4.46; 4.33 0.0384 sig
SECONDARY
Changes in Limitations When Completing High-Intensity Activity - NuBest Group Only (Within-Group Analysis)
1.13; 1.17; 1.21; 1.17; 1.08; 1.13 >0.9999
SECONDARY
Changes in Limitations When Completing Moderate-Intensity Activity - NuBest Group Only (Within-Group Analysis)
1.21; 1.13; 1.13; 1.08; 1.00; 1.08 >0.9999
SECONDARY
Changes in Limitations When Moving Around - NuBest Group Only (Within-Group Analysis)
1.00; 1.08; 1.08; 1.04; 1.00; 1.08 >0.9999
SECONDARY
Changes in Limitations When Walking 100 Meters or Climbing a Flight of Stairs - NuBest Group Only (Within-Group Analysis)
1.21; 1.08; 1.13; 1.04; 1.04; 1.08 >0.9999
SECONDARY
Changes in Limitations When Bending, Lifting, or Stooping - NuBest Group Only (Within-Group Analysis)
1.04; 1.08; 1.08; 1.00; 1.00; 1.08 >0.9999
SECONDARY
Changes in Limitations in the Kind of Schoolwork or Activities Undertaken - NuBest Group Only (Within-Group Analysis)
1.08; 1.13; 1.13; 1.08; 1.00; 1.08 >0.9999
SECONDARY
Changes in Limitations in the Amount of Time Spent Completing Schoolwork or Activities - NuBest Group Only (Within-Group Analysis)
1.13; 1.25; 1.08; 1.17; 1.00; 1.08 >0.9999
SECONDARY
Changes in Limitations During the Completion of Schoolwork or Activities - NuBest Group Only (Within-Group Analysis)
1.13; 1.17; 1.21; 1.13; 1.00; 1.08 >0.9999
SECONDARY
Change in Parents' Perception of Child's Health Compared to Other Children - NuBest Group Only (Within-Group Analysis)
1.71; 1.46; 1.54; 1.29; 1.33; 1.46 >0.9999
SECONDARY
Change in Parents' Perception of Child's Immunity - NuBest Group Only (Within-Group Analysis)
2.38; 2.21; 2.00; 2.13; 2.13; 2.04 >0.9999
SECONDARY
Change in Parents' Worry About Child's Health - NuBest Group Only (Within-Group Analysis)
2.38; 2.17; 2.38; 2.13; 2.08; 2.33 0.819
SECONDARY
Change in Parent-reported Frequency of Child's Stomach Aches - NuBest Group Only (Within-Group Analysis)
2.42; 2.17; 2.13; 2.08; 2.13; 1.92 >0.9999
SECONDARY
Change in Parent-reported Frequency of Child's Difficulty Going to the Toilet - NuBest Group Only (Within-Group Analysis)
2.33; 2.13; 1.96; 1.79; 1.71; 1.71 >0.9999
SECONDARY
Changes in Overall Health as Reported by Parents - Placebo Group Only (Within-Group Analysis)
4.05; 4.19; 4.14; 4.43; 4.19; 4.38 >0.9999
SECONDARY
Change in Parents' Perception of the Child's Health in the Future - Placebo Group Only (Within-Group Analysis)
3.48; 3.43; 3.48; 3.62; 3.62; 3.62 >0.9999
SECONDARY
Parents' Perception of the Change in Child's Health Compared to One Month Ago - Placebo Group Only (Within-Group Analysis)
3.29; 3.52; 3.57; 3.90; 3.71; 4.05 >0.9999
SECONDARY
Change in Child's Energy Levels as Reported by Parents - Placebo Group Only (Within-Group Analysis)
3.86; 3.95; 4.29; 4.33; 4.10; 4.29 0.9821
SECONDARY
Changes in Limitations When Completing High-Intensity Activity - Placebo Group Only (Within-Group Analysis)
1.38; 1.24; 1.24; 1.14; 1.14; 1.10 >0.9999
SECONDARY
Changes in Limitations When Completing Moderate-Intensity Activity - Placebo Group Only (Within-Group Analysis)
1.29; 1.24; 1.19; 1.10; 1.05; 1.10 >0.9999
SECONDARY
Changes in Limitations When Moving Around - Placebo Group Only (Within-Group Analysis)
1.10; 1.14; 1.10; 1.10; 1.14; 1.10 >0.9999
SECONDARY
Changes in Limitations When Walking 100 Meters or Climbing a Flight of Stairs - Placebo Group Only (Within-Group Analysis)
1.14; 1.14; 1.05; 1.05; 1.10; 1.05 >0.9999
SECONDARY
Changes in Limitations When Bending, Lifting, or Stooping - Placebo Group Only (Within-Group Analysis)
1.24; 1.14; 1.10; 1.10; 1.19; 1.05 >0.9999
SECONDARY
Changes in Limitations in the Kind of Schoolwork or Activities Undertaken - Placebo Group Only (Within-Group Analysis)
1.43; 1.19; 1.19; 1.14; 1.10; 1.10 >0.9999
SECONDARY
Changes in Limitations in the Amount of Time Spent Completing Schoolwork or Activities - Placebo Group Only (Within-Group Analysis)
1.43; 1.10; 1.19; 1.14; 1.14; 1.10 >0.9999
SECONDARY
Changes in Limitations During the Completion of Schoolwork or Activities - Placebo Group Only (Within-Group Analysis)
1.48; 1.24; 1.29; 1.10; 1.10; 1.05 >0.9999
SECONDARY
Change in Parents' Perception of Child's Health Compared to Other Children - Placebo Group Only (Within-Group Analysis)
1.48; 1.57; 1.38; 1.43; 1.48; 1.52 >0.9999
SECONDARY
Change in Parents' Perception of Child's Immunity - Placebo Group Only (Within-Group Analysis)
2.24; 2.24; 2.19; 2.19; 2.14; 2.00 >0.9999
SECONDARY
Change in Parents' Worry About Child's Health - Placebo Group Only (Within-Group Analysis)
2.24; 2.19; 2.10; 2.19; 2.14; 2.05 0.998
SECONDARY
Change in Parent-reported Frequency of Child's Stomach Aches - Placebo Group Only (Within-Group Analysis)
2.24; 2.05; 1.90; 1.81; 1.90; 1.86 >0.9999
SECONDARY
Change in Parent-reported Frequency of Child's Difficulty Going to the Toilet - Placebo Group Only (Within-Group Analysis)
1.90; 1.81; 1.71; 1.52; 1.57; 1.48 >0.9999

Summary

A 6-month virtual two-armed randomized double-blind placebo-controlled clinical trial. Participants will take NuBest Tall Growth Protein Powder or a placebo daily. Parents will complete questionnaires at baseline and monthly, and children will undergo cognitive assessments and height/weight measurements at specified intervals.

Eligibility Criteria

Inclusion Criteria

  • Interested in their child trialing a dietary supplement designed to improve overall health outcomes in children including height, maintenance of a healthy weight, cognitive function, immune function, and energy levels.
  • Willing to refrain from giving their child any vitamins, minerals, or herbal supplements of any kind for the duration of the study.
  • Parents willing to weigh and measure the height of their child throughout the study.
  • Generally healthy - do not have any uncontrolled chronic disease.

Exclusion Criteria

  • Any child with a history of endocrine disorder, heart disease, lung disease, kidney disease, digestive disease, or skeletal dysplasia.
  • Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Is undergoing or planning to undergo significant medical procedures in the next six months.
  • A history of severe allergic reactions, including but not limited to any of the product's ingredients.
  • Any child with a dairy allergy or lactose intolerance.
  • Has undergone any surgeries or invasive treatments in the last six months.
  • Has had any major illness in the last three months.
  • Having any planned invasive medical procedures during the study period.
  • Currently participating in any other clinical study.
  • Unwilling to follow the study protocol.
  • Any child diagnosed with attention-deficit disorder (ADD) or attention-deficit hyperactivity disorder (ADHD).
  • Any child currently taking or have taken in the last 3 months any prescription medication targeting ADD or ADHD (such as Adderall, Concerta, Focalin, Evekeo, or Ritalin).
  • Any child that is a 'fussy' eater or who the parent suspects may not tolerate consuming the test product daily for six months.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06704178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search